ClinicalTrials.gg

Program

Folic Acid

Also written as “Norgestimate; Ethinyl Estradiol; Folic acid”, “Vitamin B12, Vitamin B6, Folic acid” and “Amlodipine besylate and folic acid”.

Its studies are mostly in Hypertension · Arthritis, Rheumatoid · Vitamin B 12 Deficiency · Hypophosphatasia · Essential Hypertension, led by 4 companies.

Furthest: phase 4, since Nov 19, 200810 company-led studies, 2 open or runningNext primary completion: Jun 30, 2029 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Ausa Pharmed52 open or runningphase 4since Nov 19, 2008Nov 19, 2008Jun 30, 2029phase 4 · NCT04974151
Johnson & Johnson30 open or runningphase 1since Jun 30, 2008Jun 30, 2008none ahead
AstraZeneca10 open or runningphase 4since Aug 23, 2023Aug 23, 2023none ahead
Celltrion10 open or runningphase 1since May 22, 2013May 22, 2013none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2008First studies: 3 phase 1 studiesNew to Johnson & JohnsonJohnson & Johnson · NCT00709982, NCT00709332, NCT00709267
  2. Nov 19, 2008Shenzhen Ausa Pharmed's first study: phase 4 study in Essential HypertensionNew to Shenzhen Ausa PharmedShenzhen Ausa Pharmed · NCT00794885 · 20,702 enrolled · China
  3. May 22, 2013Celltrion's first study: phase 1 study in Arthritis, RheumatoidNew to CelltrionCelltrion · NCT01873443 · 87 enrolled · Korea, Republic of
  4. May 29, 2013Phase 4 study in HypertensionShenzhen Ausa Pharmed · NCT01871740 · China
  5. Mar 14, 2018Phase 4 study in HypertensionShenzhen Ausa Pharmed · NCT03472508 · 3,600 enrolled · China
  6. Jul 13, 20212 phase 4 studies in HypertensionShenzhen Ausa Pharmed · NCT04974151, NCT04974138
  7. Aug 23, 2023AstraZeneca's first study: phase 4 study in HypophosphatasiaNew to AstraZenecaAstraZeneca · NCT06015750

Ahead

  1. Jun 30, 2029Primary completion: phase 4 study in HypertensionShenzhen Ausa Pharmed · NCT04974151
  2. Jun 30, 2030Primary completion: phase 4 study in HypertensionShenzhen Ausa Pharmed · NCT04974138

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06015750Hypophosphatasia4WithdrawnAstraZenecaMar 13, 20300
NCT04974151Hypertension · China4RecruitingShenzhen Ausa PharmedJun 30, 202924,000
NCT04974138Hypertension · China4RecruitingShenzhen Ausa PharmedJun 30, 203032,000
NCT03472508Hypertension · China4UNKNOWNShenzhen Ausa PharmedMar 30, 20193,600
NCT01871740Hypertension · China4WithdrawnShenzhen Ausa PharmedJun 20140
NCT01873443Arthritis, Rheumatoid · Korea, Republic of1CompletedCelltrionOct 201487
NCT00794885Essential Hypertension · China4CompletedShenzhen Ausa PharmedAug 201320,702
NCT00709982Drug Interactions1CompletedJohnson & Johnson47
NCT00709332Drug Interactions1CompletedJohnson & Johnson47
NCT00709267Healthy1CompletedJohnson & Johnson12

How it is read

Names in the registry

  • “Folic Acid”, 2 entries
  • “Norgestimate; Ethinyl Estradiol; Folic acid”, 2 entries
  • “Vitamin B12, Vitamin B6, Folic acid”, 1 entry
  • “Amlodipine besylate and folic acid”, 1 entry
  • “Amlodipine besylate And Folic Acid”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.